Targeted delivery of etoposide to osteosarcoma cells using poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) nanoparticles

Authors

ESMA ALP
TAMER ÇIRAK
MURAT DEMİRBİLEK
MUSTAFA TÜRK
EYLEM GÜVEN

DOI

10.3906/biy-1612-17

Abstract

Folic acid (FA)-functionalized poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) nanoparticles were prepared to enhance the delivery efficiency of the anticancer drug etoposide for the clinical treatment of osteosarcoma. PHBV nanoparticles were synthesized by emulsification/solvent evaporation technique and obtained in the size range of 200-250 nm and zeta potential range of -21 and -27 mV. Encapsulation efficiency and in vitro drug release were studied. The cytotoxic, apoptotic, and necrotic effects of PHBV nanoparticles were also investigated using Saos-2 osteosarcoma cells. The results obtained in this study demonstrate that etoposide-loaded and FA-functionalized PHBV nanoparticles can be successfully used for targeted treatment of osteosarcoma.

Keywords

PHBV nanoparticle, folate targeting, etoposide, targeted drug delivery, osteosarcoma

First Page

719

Last Page

733

Recommended Citation

ALP, ESMA; ÇIRAK, TAMER; DEMİRBİLEK, MURAT; TÜRK, MUSTAFA; and GÜVEN, EYLEM (2017) "Targeted delivery of etoposide to osteosarcoma cells using poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) nanoparticles," Turkish Journal of Biology: Vol. 41: No. 5, Article 4. https://doi.org/10.3906/biy-1612-17
Available at: https://journals.tubitak.gov.tr/biology/vol41/iss5/4